[1]

Effi AB, Aman NA, Koui BS, et al. Immunohistochemical determination of estrogen and progesterone receptors in breast cancer: relationship with clinicopathologic factors in 302 patients in Ivory Coast[J/OL]. BMC Cancer, 2017, 17(1): 115[2021-03-29]. https://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3105-z. DOI:10.1186/s12885-017-3105-z.
[2] Harbeck N, Gnant M.  Breast cancerInterpretation of the evidence for the efficacy and safety of statin therapy[J]. Lancet, 2017, 389(10074): 1134-1150.   doi: 10.1016/S0140-6736(16)31891-8
[3] Albain KS, Barlow WE, Shak S, et al.  Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial[J]. Lancet Oncol, 2010, 11(1): 55-65.   doi: 10.1016/S1470-2045(09)70314-6
[4] Perou CM, Sørlie T, Eisen MB, et al.  Molecular portraits of human breast tumours[J]. Nature, 2000, 406(6797): 747-752.   doi: 10.1038/35021093
[5] Li H, Zhu YT, Burnside ES, et al.  MR imaging radiomics signatures for predicting the risk of breast cancer recurrence as given by research versions of MammaPrint, Oncotype DX, and PAM50 gene assays[J]. Radiology, 2016, 281(2): 382-391.   doi: 10.1148/radiol.2016152110
[6] Youk JH, Son EJ, Chung J, et al.  Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes[J]. Eur Radiol, 2012, 22(8): 1724-1734.   doi: 10.1007/s00330-012-2425-2
[7]

Camps-Herrero J. Diffusion-weighted imaging of the breast: current status as an imaging biomarker and future role[J/OL]. BJR| Open, 2019, 1(1): 20180049[2021-03-29]. https://www.birpublications.org/doi/10.1259/bjro.20180049. DOI: 10.1259/bjro.20180049.
[8] Kim SR, Paik S.  Genomics of adjuvant therapy for breast cancer[J]. Cancer J, 2011, 17(6): 500-504.   doi: 10.1097/PPO.0b013e31823e5370
[9] Goldhirsch A, Ingle JN, Gelber RD, et al.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009[J]. Ann Oncol, 2009, 20(8): 1319-1329.   doi: 10.1093/annonc/mdp322
[10] Goldhirsch A, Wood WC, Coates AS, et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J]. Ann Oncol, 2011, 22(8): 1736-1747.   doi: 10.1093/annonc/mdr304
[11] Bozkurt KK, Kapucuoğlu N.  Investigation of immunohistochemical ERα, ERβ and ERβcx expressions in normal and neoplastic breast tissues[J]. Pathol-Res Pract, 2012, 208(3): 133-139.   doi: 10.1016/j.prp.2011.12.015
[12]

Wang J, Feng L, Zhu ZT, et al. Aquaporins as diagnostic and therapeutic targets in cancer: how far we are?[J/OL]. J Transl Transl Med, 2015, 13: 1-11[2021-03-29]. https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-015-0439-7. DOI:10.1186/s12967-015-0439-7.
[13] Bharti JN, Rani P, Kamal V, et al.  Angiogenesis in breast cancer and its correlation with estrogen, progesterone receptors and other prognostic factors[J]. J Clin Diagn Res, 2015, 9(1): EC05-EC07.   doi: 10.7860/JCDR/2015/10591.5447
[14] Prat A, Pineda E, Adamo B, et al.  Clinical implications of the intrinsic molecular subtypes of breast cancer[J]. Breast, 2015, 24(Suppl 2): S26-35.   doi: 10.1016/j.breast.2015.07.008
[15] Coates AS, Winer EP, Goldhirsch A, et al.  Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015[J]. Ann Oncol, 2015, 26(8): 1533-1546.   doi: 10.1093/annonc/mdv221
[16] Valla M, Vatten LJ, Engstrøm MJ, et al.  Molecular subtypes of breast cancer: long-term incidence trends and prognostic differences[J]. Cancer Epidemiol Biomarkers Prev, 2016, 25(12): 1625-1634.   doi: 10.1158/1055-9965.EPI-16-0427
[17] 石琴, 付志明, 张文, 等.  乳腺癌动态增强磁共振成像特征与分子预后标志物的关系[J]. 肿瘤影像学, 2019, 28(6): 371-376.   doi: 10.19732/j.cnki.2096-6210.2019.06.004
Shi Q, Fu ZM, Zhang W, et al.  Correlation between dynamic contrast-enhanced magnetic resonance imaging features and molecular prognostic markers in breast cancer relationship between dynamic contrast-enhanced magnetic resonance imaging and molecular prognostic markers in breast cancer[J]. Oncoradiology, 2019, 28(6): 371-376.   doi: 10.19732/j.cnki.2096-6210.2019.06.004
[18] Net JM, Whitman GJ, Morris E, et al.  Relationships between human-extracted MRI tumor phenotypes of breast cancer and clinical prognostic indicators including receptor status and molecular subtype[J]. Curr Probl Diagn Radiol, 2019, 48(5): 467-472.   doi: 10.1067/j.cpradiol.2018.08.003
[19] Montemezzi S, Camera L, Giri MG, et al.  Is there a correlation between 3T multiparametric MRI and molecular subtypes of breast cancer?[J]. Eur J Radiol, 2018, 108: 120-127.   doi: 10.1016/j.ejrad.2018.09.024
[20] Roknsharifi S, Fishman MDC, Agarwal MD, et al.  The role of diffusion weighted imaging as supplement to dynamic contrast enhanced breast MRI: can it help predict malignancy, histologic grade and recurrence?[J]. Acad Radiol, 2019, 26(7): 923-929.   doi: 10.1016/j.acra.2018.09.003
[21] 南帅明, 黄波, 罗娅红.  不同乳腺非特殊型浸润性癌分子分型的MRI表观扩散系数特点研究[J]. 磁共振成像, 2019, 10(2): 130-135.   doi: 10.12015/issn.1674-8034.2019.02.011
Nan SM, Huang B, Luo YH.  Apparent diffusion coefficient value study in different molecular subtypes of non-specific type invasive breast carcinomas[J]. Chin J Magn Reson Imaging, 2019, 10(2): 130-135.   doi: 10.12015/issn.1674-8034.2019.02.011